Abstract
Poly-arginine peptides R18 and R18D have previously been demonstrated to be neuroprotective in ischaemic stroke models. Here we examined the proteolytic stability and efficacy of R18 and R18D in reducing infarct core growth and preserving the ischaemic penumbra following middle cerebral artery occlusion (MCAO) in the Sprague Dawley rat. R18 (300 or 1000 nmol/kg), R18D (300 nmol/kg) or saline were administered intravenously 10 min after MCAO induced using a filament. Serial perfusion and diffusion-weighted MRI imaging was performed to measure changes in the infarct core and penumbra from time points between 45- and 225-min post-occlusion. Repeated measures analyses of infarct growth and penumbral tissue size were evaluated using generalised linear mixed models (GLMMs). R18D (300 nmol/kg) was most effective in slowing infarct core growth (46.8 mm3 reduction; p < 0.001) and preserving penumbral tissue (21.6% increase; p < 0.001), followed by R18 at the 300 nmol/kg dose (core: 29.5 mm3 reduction; p < 0.001, penumbra: 12.5% increase; p < 0.001). R18 at the 1000 nmol/kg dose had a significant impact in slowing core growth (19.5 mm3 reduction; p = 0.026), but only a modest impact on penumbral preservation (6.9% increase; p = 0.062). The in vitro anti-excitotoxic neuroprotective efficacy of R18D was also demonstrated to be unaffected when preincubated for 1–3 h or overnight, in a cell lysate prepared from dying neurons or with the proteolytic enzyme, plasmin, whereas the neuroprotective efficacy of R18 was significantly reduced after a 2-h incubation. These findings highlight the capacity of poly-arginine peptides to reduce infarct growth and preserve the ischaemic penumbra, and confirm the superior efficacy and proteolytic stability of R18D, which indicates that this peptide is likely to retain its neuroprotective properties when co-administered with alteplase during thrombolysis for acute ischaemic stroke.
Similar content being viewed by others
Data Availability Statement
The data that support the findings of the present study will be made available upon request from the corresponding author.
References
Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P et al (2018) DAWN trial investigators. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med 378(1):11–21
Hill MD, Goyal M, Demchuk AM, Fisher M (2015) Ischemic stroke tissue-window in the new era of endovascular treatment. Stroke 46(8):2332–2334
Wang D, Wang Y (2019) Tissue window, not the time window, will guide acute stroke treatment. Stroke Vasc Neurol 4(1):1–2
Toni D, Risitano A, Gentile L (2020) A revolution in stroke therapy: reperfusion therapy effective even if late. Eur Heart J 22(Suppl E):E157–E161
Meloni BP, Brookes LM, Clark VW, Cross JL, Edwards AB, Anderton RS et al (2015) Poly-arginine and arginine-rich peptides are neuroprotective in stroke models. J Cereb Blood Flow Metab 35(6):993–1004
Meloni BP, Milani D, Edwards AB, Anderton RS, O’Hare Doig RL et al (2015) Neuroprotective peptides fused to arginine-rich cell penetrating peptides: neuroprotective mechanism likely mediated by peptide endocytic properties. Pharmacol Ther 153:36–54
Meloni BP, Mastaglia FL, Knuckey NW (2020) Cationic arginine-rich peptides (CARPs): a novel class of neuroprotective agents with a multimodal mechanism of action. Front Neurol 11:108
MacDougall G, Anderton RS, Ouliel E, Junjie Gao J, Redmond SL, Knuckey NW et al (2020) In vitro cellular uptake and neuroprotective efficacy of poly-arginine-18 (R18) and poly-ornithine-18 (O18) peptides: critical role of arginine guanidinium head groups for neuroprotection. Mol Cell Biochem 464(1–2):27–38
MacDougall G, Anderton RS, Mastaglia FL, Knuckey NW, Meloni BP (2019) Mitochondria and neuroprotection in stroke: cationic arginine-rich peptides (CARPS) as a novel class of mitochondria-targeted neuroprotective therapeutics. Neurobiol Dis 121:17–33
Hill MD, Goyal M, Menon BK, Nogueira RG, McTaggart RA, Demchuk AM et al (2020) Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. Lancet 395(10227):878–887
Meloni BP, South SM, Gill DA, Marriott AL, Déziel RA, Jacques A et al (2019) Poly-arginine peptides R18 and R18D improve functional outcomes after endothelin-1-induced stroke in the Sprague Dawley rat. J Neuropathol Exp Neurol 78(5):426–435
Meloni BP, Chen Y, Harrison KA, Nashed JY, Blacker DJ, South SM et al (2020) Poly-arginine peptide-18 (R18) reduces brain injury and improves functional outcomes in a non-human primate stroke model. Neurotherapeutics 17(2):627–634
Milani D, Clark VW, Cross JL, Anderton RS, Knuckey NW, Meloni BP (2016) Poly-arginine peptides reduce infarct volume in a permanent middle cerebral artery rat stroke model. BMC Neurosci 17(1):19
Milani D, Knuckey NW, Anderton RS, Cross JL, Meloni BP (2016) The R18 poly-arginine peptide is more effective than the TAT–NR2B9c (NA-1) peptide when administered 60 minutes after permanent middle cerebral artery occlusion in the rat. Stroke Res Treat 2016:2372710
Milani D, Cross JL, Knuckey NW, Blacker DJ, Anderton RS, Meloni BP (2017) Neuroprotective efficacy of R18 poly-arginine and NA-1 (TAT-NR2B9c) peptides following transient middle cerebral artery occlusion in the rat. Neurosci Res 114:9–15
Milani D, Bakeberg MC, Cross JL, Clark VW, Anderton RS, Blacker DJ et al (2018) Comparison of neuroprotective efficacy of poly-arginine R18 and R18D (D-enantiomer) peptides following permanent middle cerebral artery occlusion in the Wistar rat and in vitro toxicity studies. PLoS One 13:e0193884
Edwards AB, Cross JL, Anderton RS, Knuckey NW, Meloni BP (2018) Poly-arginine R18 and R18D (D-enantiomer) peptides reduce infarct volume and improve behavioural outcomes following perinatal hypoxic-ischaemic encephalopathy in the P7 rat. Mol Brain 11(1):8
Edwards AB, Anderton RS, Knuckey NW, Meloni BP (2018) Assessment of therapeutic window for poly-arginine-18D (R18D) in a P7 rat model of perinatal hypoxic-ischaemic encephalopathy. J Neurosci Res 96(11):1816–1826
Cesarman-Maus G, Hajjar KA (2005) Molecular mechanisms of fibrinolysis. Br J Haematol 129(3):307–321
Jung HJ, Jeong KS, Lee DG (2008) Effective antibacterial action of tat (47-58) by increased uptake into bacterial cells in the presence of trypsin. J Microbiol Biotechnol 18(5):990–996
Reese T, Bochelen D, Sauter A, Beckmann N, Rudin M (1999) Magnetic resonance angiography of the rat cerebrovascular system without the use of contrast agents. NMR Biomed 12(4):189–196
Beckman N (2000) High resolution magnetic resonance angiography non-invasively reveals mouse strain differences in the cerebrovascular anatomy in vivo. Magn Reson Med 44(2):252–258
Kim SG (1995) Quantification of relative cerebral blood flow change by flow-sensitive alternating inversion recovery (FAIR) technique application to functional mapping. Magn Reson Med 34(3):293–301
Detre JA, Leigh JS, Williams DS, Koretsky AP (1992) Perfusion imaging. Magn Reson Med 23(1):37–45
Xie J, Gallichan D, Gunn RN, Jezzard P (2008) Optimal design of pulsed arterial spin labelling MRI experiments. Magn Reson Med 59(4):826–834
Herscovitch P, Raichle ME (1985) What is the correct value for the brain-blood partition coefficient for water? J Cereb Blood Flow Metab 5(1):65–69
Kober F, Iltis I, Izquierdo M, Desrois M, Ibarrola D, Cozzone PJ et al (2004) High-resolution myocardial perfusion mapping in small animals in vivo by spin-labelling gradient-echo imaging. Magn Reson Med 51(1):62–67
Leithner C, Muller S, Fuchtemeier M, Lindaur U, Dirnagl U, Royl G (2010) Determination of the brain-blood partition coefficient for water in mice using MRI. J Cereb Blood Flow Metab 30(11):1821–1824
Dobre MC, Uğurbil K, Marjanska M (2007) Determination of blood longitudinal relaxation time (T1) at high magnetic field strengths. Magn Reson Imaging 25(5):733–735
Yushkevich PA, Piven J, Hazlett HC, Smith RG, Ho S, Gee JC et al (2006) User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage. 31(3):1116–1128
Meloni BP, Majda BT, Knuckey NW (2001) Establishment of neuronal in vitro models of ischemia in 96 well microtitre strip-plates that result in acute, progressive and delayed neuronal death. Neuroscience. 108(1):17–26
Elmquist A, Langel U (2003) In vitro uptake and stability study of pVEC and its all-D analog. Biol Chem 384(3):387–393
Tugyi R, Uray K, Iván D, Fellinger E, Perkins A, Hudecz F (2005) Partial D-amino acid substitution: improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptide. Proc Natl Acad Sci U S A 102(2):413–418
Kenna JE, Anderton RS, Knuckey NW, Meloni BP (2020) Assessment of recombinant tissue plasminogen activator (rtPA) toxicity in cultured neural cells and subsequent treatment with poly-arginine peptide R18D. Neurochem Res 45(5):1215–1229
Leithold LH, Jiang N, Post J, Ziehm T, Schartmann E, Kutzsche J et al (2016) Pharmacokinetic properties of a novel D-peptide developed to be therapeutically active against toxic β-amyloid oligomers. Pharm Res 33(2):328–336
Doranz BJ, Filion LG, Diaz-Mitoma F, Sitar DS, Sahai J, Baribaud F et al (2001) Safe use of the CXCR4 inhibitor ALX40-4C in humans. AIDS Res Hum Retrovir 17(6):475–478
Acknowledgements
We thank Prof Frank Mastaglia for editorial changes and suggestions to the manuscript.
Funding
The present study was supported by the Perron Institute for Neurological and Translational Science, and the Department of Neurosurgery at Sir Charles Gairdner Hospital.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
Bruno P. Meloni and Neville W. Knuckey are the holders of several patents regarding the use of arginine-rich peptides as neuroprotective treatments. Diego Milani, Vince W. Clark, Ryan S. Anderton, David J. Blacker, Adam Edwards, Neville W. Knuckey, and Bruno P. Meloni are shareholders in Argenica Therapeutics, which is a company developing R18 as a stroke therapeutic. The other authors declare no conflict of interest.
Ethical Approval
All work was performed in compliance with the Animal Ethics Committee of the University of Western Australia and following the guidelines outlined by the Australian Code for the Care and Use of Animals for Scientific Purposes.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Milani, D., Clark, V.W., Feindel, K.W. et al. Comparative Assessment of the Proteolytic Stability and Impact of Poly-Arginine Peptides R18 and R18D on Infarct Growth and Penumbral Tissue Preservation Following Middle Cerebral Artery Occlusion in the Sprague Dawley Rat. Neurochem Res 46, 1166–1176 (2021). https://doi.org/10.1007/s11064-021-03251-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11064-021-03251-y